Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 2/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10138565 | 0.79 | GRIN2D (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL21165989 | 0.79 | GRIN2D (0.71) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL24853842 | 0.79 | — | — | |
| SCHEMBL18720743 | 0.78 | EPHX1 (0.39) | ALDH1A1 | |
| SCHEMBL17425868 | 0.77 | GRIN2D (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL24209213 | 0.76 | — | — | |
| SCHEMBL18720725 | 0.74 | KMT2A (0.39) | ALDH1A1 | |
| SCHEMBL23900514 | 0.74 | EPHX2 (0.37) | ALDH1A1 | |
| SCHEMBL18720724 | 0.74 | EPHX2 (0.40) | ALDH1A1 | |
| SCHEMBL14608704 | 0.73 | GRIN2D (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303539-A1 | IMMUNOREGULATORY COMPOUND AND ANTITUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2023-09-28 | — | — | US | disclosed |
| EP-3939968-A1 | NOVEL COMPOUND HAVING ANTICANCER ACTIVITY, AND METHOD FOR PRODUCING SAME | Medicinal Bioconvergence Research Center (KR) | 2022-01-19 | — | — | EP | disclosed |
| US-10029993-B2 | Disubstituted 1, 2, 4-triazine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2018-07-24 | — | — | US | disclosed |
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044115-A1 | NOVEL DISUBSTITUTED 1, 2, 4-TRIAZINE COMPOUND | NR3C2, REN, CYP21A2 | GRIN2D 3208/4885GRIN3B 2989/4885GRIN1 656/4885 |
| US-20230303539-A1 | IMMUNOREGULATORY COMPOUND AND ANTITUMOR APPLICATION THEREOF | TNF, NFATC1, IL2 | GRIN2D 3766/4885GRIN3B 2366/4885GRIN1 2351/4885 |
| US-10029993-B2 | Disubstituted 1, 2, 4-triazine compound | NR3C2, REN, NR5A1 | GRIN2D 3376/4885GRIN3B 3190/4885GRIN1 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.